No abstract available
Keywords:
Complete pathologic response; Immunotherapy; Neoadjuvant; PD-L1 inhibitor; Resectable hepatocellular carcinoma.
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Carcinoma, Hepatocellular* / drug therapy
-
Carcinoma, Hepatocellular* / immunology
-
Carcinoma, Hepatocellular* / pathology
-
Carcinoma, Hepatocellular* / surgery
-
Female
-
Hepatectomy* / adverse effects
-
Hepatectomy* / methods
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immunohistochemistry
-
Immunotherapy / methods
-
Liver Neoplasms* / drug therapy
-
Liver Neoplasms* / immunology
-
Liver Neoplasms* / pathology
-
Liver Neoplasms* / surgery
-
Liver* / diagnostic imaging
-
Liver* / pathology
-
Neoadjuvant Therapy / methods*
-
Perioperative Period
-
Preoperative Care / methods
-
Tomography, X-Ray Computed / methods
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Immune Checkpoint Inhibitors
-
avelumab